N. Penel, C. Fournier, and C. Stéphanie, Études cliniques de phases 0, 1 et 2 en cancérologie : questions d'actualité, Bull Cancer, vol.97, issue.1, pp.55-63, 2010.

G. Griffiths, Clinical trials in oncology Medicine (Baltimore), pp.56-64, 2016.

I. Walker and H. Newell, Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov, pp.15-21, 2009.

B. Pdf, Available from: http://www.ecancer .fr/content/download, 2015.

J. Arrowsmith, Trial watch: Phase II failures, Nat Rev Drug Discov, vol.10, issue.5, pp.2008-2010328, 2011.
DOI : 10.1038/nrd3439

M. Slevin, J. Mossman, A. Bowling, R. Leonard, W. Steward et al., Volunteers or victims: patients' views of randomised cancer clinical trials, British Journal of Cancer, vol.71, issue.6, 1995.
DOI : 10.1038/bjc.1995.245

R. Comis, Public Attitudes Toward Participation in Cancer Clinical Trials, Journal of Clinical Oncology, vol.21, issue.5, pp.830-835, 2003.
DOI : 10.1200/JCO.2003.02.105

Z. Nurgat, W. Craig, N. Campbell, J. Bissett, J. Cassidy et al., Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy, British Journal of Cancer, vol.24, issue.6, pp.1001-1006, 2005.
DOI : 10.1136/bmj.327.7417.693

R. Sullivan, Clinical trial design in oncology, The Lancet Oncology, vol.5, issue.12, pp.759-63, 2004.
DOI : 10.1016/S1470-2045(04)01654-7

E. Kim, D. Bernstein, S. Hilsenbeck, C. Chung, A. Dicker et al., Modernizing Eligibility Criteria for Molecularly Driven Trials, Journal of Clinical Oncology, vol.33, issue.25, pp.2815-2835, 2015.
DOI : 10.1200/JCO.2015.62.1854

N. Chau, A. Florescu, K. Chan, L. Wang, E. Chen et al., Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?, BMC Cancer, vol.165, issue.1, p.426, 2011.
DOI : 10.1093/aje/kwk052

H. Arkenau, D. Olmos, J. Ang, J. Barriuso, V. Karavasilis et al., 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?, European Journal of Cancer, vol.44, issue.11, pp.1536-1576, 2008.
DOI : 10.1016/j.ejca.2008.04.017

D. Olmos, J. Ang, C. Gomez-roca, R. Morales-barrera, A. Vulink et al., Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants ??? Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients, European Journal of Cancer, vol.48, issue.4, pp.594-600, 2012.
DOI : 10.1016/j.ejca.2011.11.004

D. Olmos, A. 'hern, R. Marsoni, S. Morales, R. Gomez-roca et al., Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors, Journal of Clinical Oncology, vol.30, issue.9, pp.996-1004, 2012.
DOI : 10.1200/JCO.2010.34.5074

L. Füssenich, I. Desar, M. Peters, S. Teerenstra, W. Van-der-graaf et al., A new, simple and objective prognostic score for phase I cancer patients, European Journal of Cancer, vol.47, issue.8, pp.1152-60, 2011.
DOI : 10.1016/j.ejca.2010.12.028

C. Stavraka, D. Pinato, S. Turnbull, M. Flynn, M. Forster et al., Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials, Cancer, vol.106, issue.2, pp.262-70, 2014.
DOI : 10.1002/cncr.28381

D. Pinato, C. Stavraka, M. Flynn, M. Forster, O. Cathail et al., An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials, PLoS ONE, vol.44, issue.1, 2014.
DOI : 10.1371/journal.pone.0083279.t004

N. Penel, J. Delord, M. Bonneterre, T. Bachelot, I. Ray-coquard et al., Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics, Investigational New Drugs, vol.9, issue.1, 2009.
DOI : 10.1007/s10637-009-9224-x

A. Ploquin, D. Olmos, D. Lacombe, A. 'hern, R. Duhamel et al., Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin, British Journal of Cancer, vol.15, issue.7, pp.1025-1055, 2012.
DOI : 10.1002/cncr.24018

H. Arkenau, D. Olmos, J. Ang, J. De-bono, J. I. Kaye et al., Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience, British Journal of Cancer, vol.15, issue.6, pp.1029-1062, 2008.
DOI : 10.1093/jnci/92.3.205

H. Arkenau, J. Barriuso, D. Olmos, J. Ang, J. Bono et al., Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials, Journal of Clinical Oncology, vol.27, issue.16
DOI : 10.1200/JCO.2008.19.5081

I. Garrido-laguna, F. Janku, C. Vaklavas, G. Falchook, S. Fu et al., Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center, Cancer, vol.10, issue.5, pp.1422-1430, 2012.
DOI : 10.1002/cncr.26413

G. Sonpavde, M. Galsky, T. Hutson, V. Hoff, and D. , Patient Selection for Phase II Trials, American Journal of Clinical Oncology, vol.32, issue.2, pp.216-225, 2009.
DOI : 10.1097/COC.0b013e318172dccd

N. Penel, S. Clisant, J. Lefebvre, and A. Adenis, ???Sufficient Life Expectancy???: An Amazing Inclusion Criterion in Cancer Phase II-III Trials, Journal of Clinical Oncology, vol.27, issue.26, pp.105-105, 2009.
DOI : 10.1200/JCO.2009.24.1810

P. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez et al., Research electronic data capture (REDCap)???A metadata-driven methodology and workflow process for providing translational research informatics support, Journal of Biomedical Informatics, vol.42, issue.2, 2009.
DOI : 10.1016/j.jbi.2008.08.010

M. Schwaederle, M. Zhao, J. Lee, A. Eggermont, R. Schilsky et al., Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials, Journal of Clinical Oncology, vol.33, issue.32, pp.3817-3842, 2015.
DOI : 10.1200/JCO.2015.61.5997

E. Sanharawi, M. Naudet, and F. , Comprendre la r??gression logistique, Journal Fran??ais d'Ophtalmologie, vol.36, issue.8, 2013.
DOI : 10.1016/j.jfo.2013.05.008

P. Preux, P. Odermatt, A. Perna, B. Marin, and A. Vergnenègre, Qu'est-ce qu'une régression logistique ? Rev Mal Respir, Feb, vol.22, issue.1, pp.159-62, 2005.

J. Geyman, Evidence-Based Medicine in Primary Care: An Overview, The Journal of the American Board of Family Medicine, vol.11, issue.1, pp.46-56, 1998.
DOI : 10.3122/15572625-11-1-46

M. Bhandari and P. Giannoudis, Evidence-based medicine: What it is and what it is not, Injury, vol.37, issue.4, pp.302-308, 2006.
DOI : 10.1016/j.injury.2006.01.034

J. Yates, B. Chalmer, and F. Mckegney, Evaluation of patients with advanced cancer using the karnofsky performance status, Cancer, vol.18, issue.8, pp.2220-2224, 1980.
DOI : 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q

V. Mor, L. Laliberte, J. Morris, and M. Wiemann, The Karnofsky performance status scale: An examination of its reliability and validity in a research setting, Cancer, vol.18, issue.9, pp.2002-2009, 1984.
DOI : 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W

F. Tas, F. Sen, H. Odabas, L. K?l?c, S. Kesk?n et al., Performance status of patients is the major prognostic factor at all stages of pancreatic cancer, International Journal of Clinical Oncology, vol.23, issue.5, 2013.
DOI : 10.1007/s10147-012-0474-9

S. Lim, S. Hee, R. Quek, and M. Tao, Performance status is the single most important prognostic factor in lymphoma patients aged greater than 75 overriding other prognostic factors such as histology, Leukemia & Lymphoma, vol.4, issue.1, pp.149-51, 2008.
DOI : 10.1093/annonc/mdl034

B. Gronlund, C. Høgdall, H. Hansen, and S. Engelholm, Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer, pp.1961-1968, 2002.

A. Weizer, D. Joshi, S. Daignault, M. Kinnaman, M. Hussain et al., Performance Status is a Predictor of Overall Survival of Elderly Patients With Muscle Invasive Bladder Cancer, The Journal of Urology, vol.177, issue.4, pp.1287-93, 2007.
DOI : 10.1016/j.juro.2006.11.060

G. Corrêa, G. Bandeira, B. Cavalcanti, F. Santos, J. Neto et al., Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival, Supportive Care in Cancer, vol.38, issue.3, pp.2679-85, 2012.
DOI : 10.1007/s00520-012-1386-y

N. Penel, M. Glabbeke, S. Mathoulin-pelissier, J. I. Sleijfer, S. Bui et al., Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer ??? Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study, British Journal of Cancer, vol.17, issue.10, pp.1544-50, 2011.
DOI : 10.1634/theoncologist.10-10-833

J. Caro, M. Salas, A. Ward, and G. Goss, Anemia as an independent prognostic factor for survival in patients with cancer, Cancer, vol.308, issue.12, pp.2214-2235, 2001.
DOI : 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P

J. Garde, C. Camps, V. Iranzo, A. Juarez, Q. Gávila et al., P-761 Is anemia a prognostic factor in small cell lung carcinoma (SCLC)? Lung Cancer, p.319, 2005.

D. Kowalski, P. Badurak, P. Jaskiewicz, M. Wierzchowski, A. Janowicz-zebrowska et al., P2-193: Anaemia as prognostic and predictive factor of non-small cell lung cancer patients treated with chemo and radiotheraphy ??? retrospective analysis, Journal of Thoracic Oncology, vol.2, issue.8, pp.646-647, 2007.
DOI : 10.1097/01.JTO.0000283851.86181.35

F. Gómez, J. , J. Monzón, A. , Á. Múgica et al., Anemia como factor pronóstico independiente en pacientes con carcinoma renal. Med Clínica, pp.407-420, 2009.

S. Park, J. Lee, S. Lee, J. Park, K. Kim et al., Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer, Cancer Chemotherapy and Pharmacology, vol.40, issue.Suppl 2, pp.91-97, 2006.
DOI : 10.1007/s00280-005-0027-2

P. Hierlihy, R. Jenkin, and J. Stryker, Anemia as a prognostic factor in cancer of the cervix: a preliminary report, Can Med Assoc J, vol.100, issue.23, pp.1100-1102, 1969.

F. Donskov, Immunomonitoring and prognostic relevance of neutrophils in clinical trials, Seminars in Cancer Biology, vol.23, issue.3, pp.200-207
DOI : 10.1016/j.semcancer.2013.02.001

Z. Su, Y. Mao, P. Ouyang, J. Tang, and F. Xie, Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact, PLOS ONE, vol.189, issue.9, p.136752, 2015.
DOI : 10.1371/journal.pone.0136752.s001

M. Worley, C. Nitschmann, M. Shoni, J. Rauh-hain, K. Williams et al., Preoperative Leukocytosis Imposes an Increased Risk of Recurrence and Death Among Patients With Nonendometrioid Endometrial Carcinoma, International Journal of Gynecological Cancer, vol.23, issue.2, 2013.
DOI : 10.1097/IGC.0b013e31827da21b

K. So, J. Hong, H. Jin, J. Kim, J. Song et al., The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: A retrospective cohort study, Gynecologic Oncology, vol.132, issue.3
DOI : 10.1016/j.ygyno.2014.01.010

Y. Chen, I. Chen, I. Lin, and S. Kao, Prognostic value of hypercalcaemia and leucocytosis in resected oral squamous cell carcinoma, British Journal of Oral and Maxillofacial Surgery, vol.52, issue.5, 2014.
DOI : 10.1016/j.bjoms.2014.02.014

R. Banerjee, G. Roxin, M. Eliasziw, K. Joseph, A. Maclean et al., The Prognostic Significance of Pretreatment Leukocytosis in Patients With Anal Cancer Treated With Radical Chemoradiotherapy or Radiotherapy, Diseases of the Colon & Rectum, vol.56, issue.9, pp.1036-1078, 2013.
DOI : 10.1097/DCR.0b013e31829ab0d4

S. Mabuchi, Y. Matsumoto, T. Hamasaki, M. Kawano, T. Hisamatsu et al., Elevated White Blood Cell Count at the Time of Recurrence Diagnosis Is an Indicator of Short Survival in Patients With Recurrent Cervical Cancer, International Journal of Gynecological Cancer, 2012.
DOI : 10.1097/IGC.0b013e31826ea0eb

I. Kasuga, S. Makino, H. Kiyokawa, H. Katoh, Y. Ebihara et al., Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer, 2001.

S. Teramukai, T. Kitano, Y. Kishida, M. Kawahara, K. Kubota et al., Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03, European Journal of Cancer, vol.45, issue.11, pp.1950-1958, 2009.
DOI : 10.1016/j.ejca.2009.01.023

P. Corrie, J. Shaw, and R. Harris, Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study, BMJ, vol.327, issue.7410, pp.320-321, 2003.
DOI : 10.1136/bmj.327.7410.320

A. Johnsen, A. Damkier, T. Vejlgaard, J. Lindschou, P. Sjøgren et al., A randomised, multicentre clinical trial of specialised palliative care plus standard treatment versus standard treatment alone for cancer patients with palliative care needs: the Danish palliative care trial (DanPaCT) protocol, BMC Palliative Care, vol.157, issue.1, p.37, 2013.
DOI : 10.7326/0003-4819-157-6-201209180-00537

G. Vanbutsele, S. Van-belle, D. Laat, M. Surmont, V. Geboes et al., The systematic early integration of palliative care into multidisciplinary oncology care in the hospital setting (IPAC), a randomized controlled trial: the study protocol, BMC Health Services Research, vol.38, issue.February 2012, p.554, 2015.
DOI : 10.1186/s12913-015-1207-3

D. Gupta, J. Grutsch, and C. Lis, Comparison of two quality of life instruments for cancer patients: the Ferrans and Powers Quality of Life Index and the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30, J Soc Integr Oncol, vol.6, issue.1, p.13, 2008.

C. Quinten, J. Maringwa, C. Gotay, F. Martinelli, C. Coens et al., Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival, JNCI Journal of the National Cancer Institute, vol.103, issue.24
DOI : 10.1093/jnci/djr485